海索比妥钠 | 50-09-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 海索比妥钠
• 英文名称: 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-, sodium salt (1:1)
• CAS: 50-09-9
• 化学式: C12H16N2NaO3
• 分子量: 259.26
• InChiKey: SVNBLYILNKAFQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.82
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  66.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• COMPOSITIONS OF COMPOUNDS AND USES THEREOF
  申请人：VM Oncology LLC

  公开号：US20150218132A1

  公开（公告）日：2015-08-06

  The present disclosure relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same. The disclosure further concerns the use of such compounds in the treatment and/or prevention of certain types of cancers, pain, inflammation, restenosis, atherosclerosis, psoriasis, thrombosis, Alzheimer's, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination.

  本公开涉及新型合成取代杂环化合物和含有这些化合物的药物组合物。该公开进一步涉及利用这些化合物治疗和/或预防某些类型的癌症、疼痛、炎症、再狭窄、动脉粥样硬化、牛皮癣、血栓形成、阿尔茨海默病、与失髓鞘形成或脱髓鞘有关的疾病、紊乱、损伤或功能障碍。
• Piperidine compounds, method for preparation thereof, and a pharamceutical composition comprising the same
  申请人：HOKURIKU PHARMACEUTICAL CO., LTD.

  公开号：EP0451772A1

  公开（公告）日：1991-10-16

  Novel piperidine compounds represented by the following formula (I): wherein Y represents an alkylene group having 1 to 7 carbon atoms; A is a group represented by formula I-a or formula I-b: wherein X represents -CH₂-S- or -S-; and R represents a hydrogen atom or a lower alkyl group with a proviso that A is a group represented by formula I-a, or R represents a hydrogen atom with a proviso that A is a group represented by formula I-b and pharmacologically acceptable salts thereof are disclosed. Also disclosed are a method for preparing the same; a pharmaceutical composition comprising the same; an antiallergic agent and an agent for bronchial asthma comprising the same; and a method for treatment of an allergic disease or bronchial asthma comprising the step of administering the same.

  本发明公开了以下式子（I）所表示的新型哌啶化合物：其中，Y代表具有1至7个碳原子的烷基；A是由式子I-a或式子I-b表示的基团：其中，X代表-CH₂-S-或-S-；R代表氢原子或较低的烷基，但在A是由式子I-a表示的基团时，R代表氢原子；在A是由式子I-b表示的基团时，R代表氢原子，其药理学上可接受的盐也被揭示。本发明还公开了一种制备该化合物的方法；包含该化合物的制药组合物；包含该化合物的抗过敏剂和支气管哮喘剂；以及通过给予该化合物进行治疗过敏性疾病或支气管哮喘的方法。
• [EN] AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM<br/>[FR] DERIVES D'ACIDES AMINES, COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES ET PROCEDES DE PREPARATION DE CEUX-CI
  申请人：DR. KARL THOMAE GMBH

  公开号：WO1997019911A1

  公开（公告）日：1997-06-05

  (EN) The invention relates to new amino acid derivatives of general formula (I), wherein B, T, Z, Y, V and n are defined as in claim 1, the tautomers, diastereomers and enantiomers thereof, the mixtures thereof and the salts thereof, particularly their physiologically acceptable salts with inorganic or organic acids or bases which have valuable pharmacological properties, particularly selective NPY-antagonist properties, pharmaceutical compositions containing these compounds, the use thereof and processes for preparing them.(FR) L'invention concerne des nouveaux dérivés d'acides aminés de la formule générale (I), dans laquelle B, T, Z, Y, V et n sont tels que définis dans la revendication 1. L'invention concerne également des tautomères, diastéréomères et énantiomères de ces dérivés et leurs mélanges, ainsi que des sels de ces dérivés, notamment des sels d'addition d'acides ou de bases inorganiques ou organiques, acceptables sur le plan physiologique. Ces dérivés possèdent des propriétés pharmacologiques précieuses, notamment des propriétés antagonistes du neuropeptide Y. On décrit encore des compositions pharmaceutiques contenant ces composés ainsi que l'utilisation et des procédés de préparation de celles-ci.

  本发明涉及一般式(I)的新型氨基酸衍生物，其中B、T、Z、Y、V和n如权利要求1所定义，其互变异构体、对映异构体和外消旋体，以及它们的混合物和盐，特别是它们的生理上可接受的无机或有机酸或碱盐，具有有价值的药理学特性，特别是选择性NPY-拮抗剂特性，还涉及含有这些化合物的制药组合物、它们的用途以及制备它们的过程。
• Pharmaceutical compositions for prevention of overdose or abuse
  申请人：Mickle Travis

  公开号：US20060014697A1

  公开（公告）日：2006-01-19

  The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.

  本发明涉及制药组合物，其中化学基团连接到活性剂上，以大大降低活性剂引起过量或被滥用的潜力。当以适当剂量给予时，该制药组合物提供与母体活性剂类似的治疗活性。
• Multi-Layer Tablets and Bioadhesive Dosage Forms
  申请人：Nangia Avinash

  公开号：US20080311191A1

  公开（公告）日：2008-12-18

  Bioadhesives coatings increase the gastrointestinal retention time of orally-ingested medicaments. Certain bioadhesive coatings producing a fracture strength of at least 100 N/m 2 , as measured on rat intestine, when applied to at least one surface of a pharmaceutical dosage form for oral delivery of a drug, result in a gastrointestinal retention time of at least 4 hours in a fed beagle dog model, during which the drug is released from the dosage form. Multi-layer tablets, particularly those including hydrophobic excipients, are useful in administering hygroscopic and/or deliquescent drugs. In addition, varying the amount of drug in multi-layer tablets allows the release rate of the drug to be controlled.

  生物粘合剂涂层可以增加口服药物的胃肠道保留时间。当应用于至少一种药物剂型的表面以口服给药时，产生至少100 N/m²的断裂强度的某些生物粘合剂涂层（在大鼠肠道上测量）可导致在饲养的比格犬模型中至少保留4小时的胃肠道保留时间，在此期间药物从剂型中释放。多层片剂，特别是包括疏水助剂的多层片剂，可用于给予吸湿性和/或易溶性药物。此外，改变多层片剂中药物的量可以控制药物的释放速率。